

PRESS RELEASE



www.inhibitex.com

FOR IMMEDIATE RELEASE

**Inhibitex to Present at the
Jefferies 2011 Global Healthcare Conference**

ATLANTA, Georgia – June 1, 2011 – Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell Plumb, president and chief executive officer, will present an overview of the Company and an update of its pipeline of differentiated anti-infective compounds at the Jefferies 2011 Global Healthcare Conference on June 6, 2011 at 8:00 AM (EDT). The conference is being held at the Grand Hyatt Hotel in New York City.

About Inhibitex

Inhibitex, Inc., is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company's clinical-stage pipeline includes FV-100, a nucleoside inhibitor in Phase II for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1b for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM[®] protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1 clinical trial. For additional information about the Company, please visit www.inhibitex.com.

Inhibitex[®] and MSCRAMM[®] are registered trademarks of Inhibitex, Inc.

Contacts:

Russell H. Plumb
Chief Executive Officer
(678) 746-1136
rplumb@inhibitex.com

Lee M. Stern
The Trout Group
(646) 378-2922
lstern@troutgroup.com